SII Stopped Covishield Production In December 2021, No Takers For Booster Shots As People Are Fed Up: Poonawalla
Indian Vaccine Giant Serum Institute Eyes Global Expansion, Mulls Setting Up Its First Manufacturing Plant In Africa
Invest In India For High-Quality, Large-Scale Tesla EV Manufacturing If Twitter Bid Fails: SII's Adar Poonawalla To Elon Musk
As India Crosses 100 Crore Covid-19 Vaccinations, Here Are Four Things We Need To Realise
Why Adar Poonawalla Should Get Padma Vibhushan This Year
Despite WHO Clearance, EU Green Pass Eligibility List Excludes Covishield
Petition Filed In Bombay HC Seeking Z+ Security For SII CEO Adar Poonawalla, His Family
BJP Will Win If It Chooses The Right Battlefield: The Fight Is For Dharma, Not Secular Bunkum
India Likely To Face Vaccine Shortage For Next Few Months: Serum Institute’s CEO Adar Poonawalla
Getting Threatening Calls From Very Powerful People, May Start Production In Britain: Adar Poonawalla
As Covid-19 Cases Rise, Serum Institute Plans To Begin Overseas Production Of Covishield Vaccine: Report
Raw Materials Are Not Needed For Manufacturing Of Covishield, But For Covovax, Serum Institute To US Govt
Serum Institute CEO Adar Poonawalla To Get 'Y' Category Security On All-India Basis After Threats Over Vaccine Supplies
In This Global Village, Nobody Is OK If All Are Not OK – Musings Of A 94-Year-Old
No US Confirmation Of Lifting Ban On Export Of Vaccine Raw Materials
Lift Embargo On Vaccine Raw Material Exports: Serum Institute's Adar Poonawalla Urges US President Biden
How Bharat Biotech Plans To Overcome Production Challenges Due To Export Restrictions On Raw Materials By US
US And Europe Have Banned Export Of Critical Raw Materials Needed To Manufacture Covid Vaccines: Adar Poonawalla
Status Check: No, Centre Is NOT 'Sitting On' Approvals To Other Vaccines
Serum Institute Begins Phase Two And Three Bridging Trials Of Covid-19 Vaccine Candidate Covovax In India
Adar Poonawalla Picks Up Majority Stake In NBFC Magma Fincorp; Shares Hit 10 Per Cent Upper Circuit
SII To Export Covishield Vaccine Only After Meeting Indian Demand, Earmarks 100 Million Doses For Next Two Months
Serum Institute Aims To Have 100 Million Doses Of Oxford-AstraZeneca's Covid-19 Vaccine Ready By December
Oxford-AstraZeneca Covid-19 Vaccine Likely To Be Ready For Use As Early As December: Serum Institute CEO
Health Ministry Says It Doesn't Agree With Calculation Of Rs 80,000 Crore For Covid-19 Vaccine Distribution
Oxford's Covid-19 Vaccine To Be Available In India By Year End: Serum Institute CEO Adar Poonawalla
